Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

An Intracerebral Hemorrhage Care Bundle Is Associated with Lower Case Fatality.

Parry-Jones AR, Sammut-Powell C, Paroutoglou K, Birleson E, Rowland J, Lee S, Cecchini L, Massyn M, Emsley R, Bray B, Patel H.

Ann Neurol. 2019 Oct;86(4):495-503. doi: 10.1002/ana.25546. Epub 2019 Aug 16.

2.

Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status.

Albero-González R, Hernández-Llodrà S, Juanpere N, Lorenzo M, Lloret A, Segalés L, Duran X, Fumadó L, Cecchini L, Lloreta-Trull J.

Virchows Arch. 2019 Aug;475(2):223-231. doi: 10.1007/s00428-019-02591-z. Epub 2019 Jun 17.

PMID:
31209634
3.

SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.

Hernández-Llodrà S, Segalés L, Safont A, Juanpere N, Lorenzo M, Fumadó L, Rodríguez-Vida A, Cecchini L, Bellmunt J, Lloreta-Trull J.

Prostate. 2019 Jul;79(10):1156-1165. doi: 10.1002/pros.23830. Epub 2019 May 15.

PMID:
31090082
4.

Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome.

Segalés L, Juanpere N, Lorenzo M, Albero-González R, Fumadó L, Cecchini L, Bellmunt J, Lloreta-Trull J, Hernández-Llodrà S.

Virchows Arch. 2019 Oct;475(4):457-466. doi: 10.1007/s00428-019-02573-1. Epub 2019 Apr 23.

PMID:
31016435
5.

Structural differences in the diaphragm of patients following controlled vs assisted and spontaneous mechanical ventilation.

Marin-Corral J, Dot I, Boguña M, Cecchini L, Zapatero A, Gracia MP, Pascual-Guardia S, Vilà C, Castellví A, Pérez-Terán P, Gea J, Masclans JR.

Intensive Care Med. 2019 Apr;45(4):488-500. doi: 10.1007/s00134-019-05566-5. Epub 2019 Feb 21.

PMID:
30790029
6.

Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study.

Sureda A, Fumadó L, Ferrer M, Garín O, Bonet X, Castells M, Mir MC, Abascal JM, Vigués F, Cecchini L, Suárez JF.

Health Qual Life Outcomes. 2019 Jan 14;17(1):11. doi: 10.1186/s12955-019-1082-4.

7.

Diagnostic and Prognostic Performance of Secreted Protein Acidic and Rich in Cysteine (SPARC) Assay for Detecting Primary and Recurrent Urinary Bladder Cancer.

Critselis E, Rava M, Marquez M, Lygirou V, Chatzicharalambous D, Liapi P, Lichtinghagen R, Brand K, Cecchini L, Vlahou A, Malats N, Zoidakis J.

Proteomics Clin Appl. 2019 Mar;13(2):e1800148. doi: 10.1002/prca.201800148. Epub 2019 Jan 30.

PMID:
30632279
8.

Micronuclei frequency in urothelial cells of bladder cancer patients, as a biomarker of prognosis.

Espinoza F, Cecchini L, Morote J, Marcos R, Pastor S.

Environ Mol Mutagen. 2019 Mar;60(2):168-173. doi: 10.1002/em.22252. Epub 2018 Oct 4.

PMID:
30284731
9.

Factors associated with renal function compensation after donor nephrectomy.

Burballa C, Crespo M, Redondo-Pachón D, Pérez-Sáez MJ, Arias-Cabrales C, Mir M, Francés A, Fumadó L, Cecchini L, Pascual J.

Nefrologia. 2018 Sep - Oct;38(5):528-534. doi: 10.1016/j.nefro.2018.02.008. English, Spanish.

10.

Use of agricultural by-products in the development of an agro-energy chain: A case study from the Umbria region.

Venanzi S, Pezzolla D, Cecchini L, Pauselli M, Ricci A, Sordi A, Torquati B, Gigliotti G.

Sci Total Environ. 2018 Jun 15;627:494-505. doi: 10.1016/j.scitotenv.2018.01.176. Epub 2018 Feb 3.

PMID:
29426172
11.

ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression.

Hernández-Llodrà S, Juanpere N, de Muga S, Lorenzo M, Gil J, Font-Tello A, Agell L, Albero-González R, Segalés L, Merino J, Serrano L, Fumadó L, Cecchini L, Lloreta-Trull J.

Oncotarget. 2017 May 26;8(43):74106-74118. doi: 10.18632/oncotarget.18266. eCollection 2017 Sep 26.

12.

Mediterranean Dietary Pattern is Associated with Low Risk of Aggressive Prostate Cancer: MCC-Spain Study.

Castelló A, Boldo E, Amiano P, Castaño-Vinyals G, Aragonés N, Gómez-Acebo I, Peiró R, Jimenez-Moleón JJ, Alguacil J, Tardón A, Cecchini L, Lope V, Dierssen-Sotos T, Mengual L, Kogevinas M, Pollán M, Pérez-Gómez B; MCC-Spain Researchers.

J Urol. 2018 Feb;199(2):430-437. doi: 10.1016/j.juro.2017.08.087. Epub 2017 Aug 23.

PMID:
28842246
13.

MDRD or CKD-EPI for glomerular filtration rate estimation in living kidney donors.

Burballa C, Crespo M, Redondo-Pachón D, Pérez-Sáez MJ, Mir M, Arias-Cabrales C, Francés A, Fumadó L, Cecchini L, Pascual J.

Nefrologia. 2018 Mar - Apr;38(2):207-212. doi: 10.1016/j.nefro.2017.02.007. Epub 2017 Apr 12. English, Spanish.

14.

FOXO1 down-regulation is associated with worse outcome in bladder cancer and adds significant prognostic information to p53 overexpression.

Lloreta J, Font-Tello A, Juanpere N, Frances A, Lorenzo M, Nonell L, de Muga S, Vázquez I, Cecchini L, Hernández-Llodrà S.

Hum Pathol. 2017 Apr;62:222-231. doi: 10.1016/j.humpath.2016.12.022. Epub 2017 Jan 11.

PMID:
28087474
15.

Carbon footprint of conventional and organic beef production systems: An Italian case study.

Buratti C, Fantozzi F, Barbanera M, Lascaro E, Chiorri M, Cecchini L.

Sci Total Environ. 2017 Jan 15;576:129-137. doi: 10.1016/j.scitotenv.2016.10.075. Epub 2016 Oct 23.

PMID:
27783931
16.

Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.

Hernández S, Font-Tello A, Juanpere N, de Muga S, Lorenzo M, Salido M, Fumadó L, Serrano L, Cecchini L, Serrano S, Lloreta J.

Prostate. 2016 Jun;76(9):854-65. doi: 10.1002/pros.23176. Epub 2016 Mar 9.

PMID:
26959281
17.

Twelve Core Template Prostate Biopsy is an Unreliable Tool to Select Patients Eligible for Focal Therapy.

Fumadó L, Cecchini L, Juanpere N, Ubré A, Lorente JA, Alcaraz A.

Urol Int. 2015;95(2):197-202. doi: 10.1159/000381559. Epub 2015 Apr 18.

PMID:
25896142
18.

Clinical evidence for three distinct gastric cancer subtypes: time for a new approach.

Bittoni A, Scartozzi M, Giampieri R, Faloppi L, Bianconi M, Mandolesi A, Del Prete M, Pistelli M, Cecchini L, Bearzi I, Cascinu S.

PLoS One. 2013 Nov 12;8(11):e78544. doi: 10.1371/journal.pone.0078544. eCollection 2013.

19.

Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients.

Giampieri R, Scartozzi M, Loretelli C, Piva F, Mandolesi A, Lezoche G, Del Prete M, Bittoni A, Faloppi L, Bianconi M, Cecchini L, Guerrieri M, Bearzi I, Cascinu S.

PLoS One. 2013 Sep 4;8(9):e72843. doi: 10.1371/journal.pone.0072843. eCollection 2013.

20.

Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation.

Giampieri R, Scartozzi M, Del Prete M, Maccaroni E, Bittoni A, Faloppi L, Bianconi M, Cecchini L, Cascinu S.

Crit Rev Oncol Hematol. 2013 Nov;88(2):272-83. doi: 10.1016/j.critrevonc.2013.05.008. Epub 2013 Jun 24. Review.

PMID:
23806981
21.

End-of-life decision making in respiratory failure. The therapeutic choices in chronic respiratory failure in a 7-item questionnaire.

Rinnenburger D, Alma MG, Bigioni D, Brunetti G, Liberati C, Magliacani V, Monaco G, Reggiani L, Taronna G, Cecchini L.

Ann Ist Super Sanita. 2012;48(3):328-33. doi: 10.4415/ANN_12_03_14.

22.

[First investigation on some aspects of Italian physicians: a statistical study].

Palmieri B, Iannitti T, Capone S, Monaco M, Cecchini L.

Clin Ter. 2012;163(2):149-53. Italian.

PMID:
22555832
23.

Role of antithrombotic agents in heart failure.

Cleland JG, Mumtaz S, Cecchini L.

Curr Cardiol Rep. 2012 Jun;14(3):314-25. doi: 10.1007/s11886-012-0266-x. Review.

PMID:
22467260
24.

Preoperative prediction of pathologically insignificant prostate cancer in radical prostatectomy specimens: the role of prostate volume and the number of positive cores.

Raventós CX, Orsola A, de Torres I, Cecchini L, Trilla E, Planas J, Morote J.

Urol Int. 2010;84(2):153-8. doi: 10.1159/000277591. Epub 2010 Mar 4.

PMID:
20215818
25.

Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.

Orsola A, Cecchini L, Raventós CX, Trilla E, Planas J, Landolfi S, de Torres I, Morote J.

BJU Int. 2010 Jan;105(2):202-7. doi: 10.1111/j.1464-410X.2009.08694.x. Epub 2009 Jun 24.

26.

Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.

Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.

BJU Int. 2009 Dec;104(11):1637-40. doi: 10.1111/j.1464-410X.2009.08622.x. Epub 2009 Jun 22.

27.

Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis.

Mollica C, Paone G, Conti V, Ceccarelli D, Schmid G, Mattia P, Perrone N, Petroianni A, Sebastiani A, Cecchini L, Orsetti R, Terzano C.

Respiration. 2010;79(3):209-15. doi: 10.1159/000225932. Epub 2009 Jun 17.

28.

Re: Marko Babjuk, Willem Oosterlinck, Richard Sylvester, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303-14.

Orsola A, Cecchini L, Morote J.

Eur Urol. 2009 Jan;55(1):e15-6; author reply e17-8. doi: 10.1016/j.eururo.2008.07.071. Epub 2008 Aug 5. No abstract available.

PMID:
18692301
29.

Is there a relationship between prostate volume and Gleason score?

Mir MC, Planas J, Raventos CX, de Torres IM, Trilla E, Cecchini L, Orsola A, Morote J.

BJU Int. 2008 Aug 5;102(5):563-5. doi: 10.1111/j.1464-410X.2008.07696.x. Epub 2008 May 12.

30.

Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R.

J Urol. 2007 Oct;178(4 Pt 1):1290-5. Epub 2007 Aug 14.

PMID:
17698136
31.

Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.

Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.

Urology. 2007 Mar;69(3):500-4.

PMID:
17382153
32.

Statins and the effect of BCG on bladder cancer.

Orsola A, Cecchini L, Bellmunt J.

N Engl J Med. 2007 Mar 22;356(12):1276; author reply 1276-7. No abstract available.

PMID:
17380586
33.

The relationship between daily calcium intake and bone mineral density in men with prostate cancer.

Planas J, Morote J, Orsola A, Salvador C, Trilla E, Cecchini L, Raventós CX.

BJU Int. 2007 Apr;99(4):812-5; discussion 815-6.

34.

Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.

Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, Catalán R, Reventós J.

Urol Int. 2006;77(2):135-8.

PMID:
16888418
35.

Correlation between the biopsies in marginal donor kidneys for transplantation: is it necessary to biopsy both kidneys?

Esquena S, Planas J, Abascal JM, Trilla E, Cecchini L, Raventós CX, Morote J.

Transplant Proc. 2006 Jun;38(5):1270-3.

PMID:
16797279
36.

Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.

Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.

J Urol. 2006 May;175(5):1679-83; discussion 1683.

PMID:
16600728
37.

Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer.

Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, Orsola A, Planas J, Catalán R, Reventós J.

Int J Biol Markers. 2005 Oct-Dec;20(4):209-16.

PMID:
16398402
38.

Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer.

Morote J, Esquena S, Orsola A, Salvador C, Trilla E, Cecchini L, Raventós CX, Planas J, Catalán R, Reventós J.

Anticancer Drugs. 2005 Sep;16(8):863-6.

PMID:
16096434
39.

Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy.

Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, Catalán R, Reventós J.

Int J Biol Markers. 2005 Apr-Jun;20(2):119-22.

PMID:
16011042
40.

Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events.

Petrosillo N, Chinello P, Proietti MF, Cecchini L, Masala M, Franchi C, Venditti M, Esposito S, Nicastri E.

Clin Microbiol Infect. 2005 Aug;11(8):682-3. No abstract available.

41.

Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients.

Orsola A, Trias I, Raventós CX, Español I, Cecchini L, Búcar S, Salinas D, Orsola I.

Eur Urol. 2005 Aug;48(2):231-8; discussion 238.

PMID:
15963635
42.

Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy.

Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Ravents CX, Cataln R, Revents J.

Int J Biol Markers. 2005 Apr - Jun;20(2):119-222. doi: 10.5301/JBM.2008.1427.

PMID:
28207137
43.

Renal collecting (Bellini) duct carcinoma displays similar characteristics to upper tract urothelial cell carcinoma.

Orsola A, Trias I, Raventós CX, Español I, Cecchini L, Orsola I.

Urology. 2005 Jan;65(1):49-54. Review.

PMID:
15667862
44.

Noninvasive positive pressure ventilation using a helmet in patients with acute exacerbation of chronic obstructive pulmonary disease: a feasibility study.

Antonelli M, Pennisi MA, Pelosi P, Gregoretti C, Squadrone V, Rocco M, Cecchini L, Chiumello D, Severgnini P, Proietti R, Navalesi P, Conti G.

Anesthesiology. 2004 Jan;100(1):16-24.

PMID:
14695719
45.

Gender-related differences in clinical and pathological characteristics and therapy of bladder cancer.

Puente D, Malats N, Cecchini L, Tardón A, García-Closas R, Serra C, Carrato A, Sala M, Boixeda R, Dosemeci M, Real FX, Kogevinas M; EPICURO Study Group Investigators.

Eur Urol. 2003 Jan;43(1):53-62.

PMID:
12507544
46.

[Brucellar spinal abscess. Case report]

Cecchini L, Coari G, Iagnocco A, Valesini G.

Reumatismo. 2001;53(3):229-231. Italian.

47.

Polarized Th2 like cells, in the absence of Th0 cells, are responsible for lymphocyte produced IL-4 in high IgE-producer schistosomiasis patients.

Dutra WO, Correa-Oliveira R, Dunne D, Cecchini LF, Fraga L, Roberts M, Soares-Silveira AM, Webster M, Yssel H, Gollob KJ.

BMC Immunol. 2002 Jul 6;3:8.

48.

Continued antigen stimulation is not required during CD4(+) T cell clonal expansion.

Lee WT, Pasos G, Cecchini L, Mittler JN.

J Immunol. 2002 Feb 15;168(4):1682-9.

49.

Non-invasive pressure support ventilation in acute hypoxemic (non hypercapnic) respiratory failure. Observations in Respiratory Intermediate Intensive Care Unit.

Mollica C, Brunetti G, Buscajoni M, Cecchini L, Maialetti E, Marazzi M, Principe R, Sabato R, Antonini VE.

Minerva Anestesiol. 2001 Mar;67(3):107-15.

PMID:
11337642
50.

Validation of the 13C-urea breath test for the diagnosis of Helicobacter pylori infection in children: a multicenter study.

Bazzoli F, Cecchini L, Corvaglia L, Dall'Antonia M, De Giacomo C, Fossi S, Casali LG, Gullini S, Lazzari R, Leggeri G, Lerro P, Valdambrini V, Mandrioli G, Marani M, Martelli P, Miano A, Nicolini G, Oderda G, Pazzi P, Pozzato P, Ricciardiello L, Roda E, Simoni P, Sottili S, Zagari RM.

Am J Gastroenterol. 2000 Mar;95(3):646-50.

PMID:
10710052

Supplemental Content

Loading ...
Support Center